- Home
- FGI vs SNGX Comparison
FGI vs SNGX Comparison
Compare FGI & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGI
- SNGX
- Stock Information
- Founded
- FGI 1987
- SNGX 1987
- Country
- FGI United States
- SNGX United States
- Employees
- FGI N/A
- SNGX N/A
- Industry
- FGI Industrial Specialties
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- FGI Industrials
- SNGX Health Care
- Exchange
- FGI Nasdaq
- SNGX Nasdaq
- Market Cap
- FGI 5.5M
- SNGX 6.5M
- IPO Year
- FGI 2022
- SNGX 1987
- Fundamental
- Price
- FGI $0.65
- SNGX $1.28
- Analyst Decision
- FGI
- SNGX
- Analyst Count
- FGI 0
- SNGX 0
- Target Price
- FGI N/A
- SNGX N/A
- AVG Volume (30 Days)
- FGI 163.3K
- SNGX 2.7M
- Earning Date
- FGI 08-06-2025
- SNGX 08-08-2025
- Dividend Yield
- FGI N/A
- SNGX N/A
- EPS Growth
- FGI N/A
- SNGX N/A
- EPS
- FGI N/A
- SNGX N/A
- Revenue
- FGI $134,277,102.00
- SNGX $2,342.00
- Revenue This Year
- FGI $7.72
- SNGX N/A
- Revenue Next Year
- FGI $6.94
- SNGX N/A
- P/E Ratio
- FGI N/A
- SNGX N/A
- Revenue Growth
- FGI 11.13
- SNGX N/A
- 52 Week Low
- FGI $0.46
- SNGX $1.09
- 52 Week High
- FGI $1.20
- SNGX $8.55
- Technical
- Relative Strength Index (RSI)
- FGI 48.82
- SNGX 34.55
- Support Level
- FGI $0.64
- SNGX $1.09
- Resistance Level
- FGI $0.67
- SNGX $1.88
- Average True Range (ATR)
- FGI 0.09
- SNGX 0.14
- MACD
- FGI 0.00
- SNGX -0.01
- Stochastic Oscillator
- FGI 29.03
- SNGX 22.78
About FGI FGI Industries Ltd.
FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).